The antibacterial textile market is undergoing a quiet rule restructuring. In June 2025, the revision task for the national standard 'Evaluation of Antibacterial Performance of Textiles Part 2: Absorption Method' was assigned, and the review meeting was held in Zhejiang, nearly 20 years after the previous version. This signals that the antibacterial evaluation system, in use for two decades, will be systematically replaced, redefining technical thresholds and compliance costs across the industry.
Revision Roadmap: Dual-Track Progress and Clear Timeline
The revision is proceeding in phases. The task for Part 3 (Shake Flask Method) was assigned in June 2024, and the standard has been completed and is now in the approval stage, expected to fully replace GB/T 20944.3-2008 upon release. The task for Part 2 (Absorption Method) was assigned in June 2025; the review meeting indicates that technical content has reached consensus, and the standard will move to the approval process. Both standards fully replace the old versions, signaling a systemic upgrade rather than minor amendments.
Drafting units include testing institutions, research institutes, brand companies, and new material enterprises, reflecting a balance between technical advancement and industrial practicality. For the supply chain, the timeline is clear—the shake flask method is imminent, with the absorption method following. Companies that delay adjustments until the new standards are officially implemented may face non-compliant testing or labeling issues.
Industry Impact: From Concept Premium to Technology Premium
Over the past two decades, antibacterial technology applications have expanded from underwear and socks to sportswear, medical textiles, and home textiles, making antibacterial claims a common selling point. However, old testing methods and technical requirements have lagged behind new materials and processes, leading to inconsistent evaluation criteria and room for exaggerated claims. The revision essentially returns to the authenticity of antibacterial function—testing methods will better reflect real-world usage, and results will be more quantifiable, meaning companies can no longer rely on vague labeling or marginal data for competitive advantage.
For manufacturers, the most direct impact is rising testing costs and R&D investment. New standards may introduce stricter bacterial strains, culture conditions, and evaluation indicators, increasing equipment updates and validation costs, particularly pressuring SMEs. Conversely, this is also an opportunity for consolidation: companies with solid technical reserves and proprietary antibacterial formulations will gain higher market recognition, shifting pricing logic from concept premium to technology premium.
For buyers and brands, standard upgrades change supply chain screening rules. Reliance on third-party reports remains valid, but the standard version becomes a critical variable—old reports may lose value after new standards are implemented. Therefore, buyers must re-audit suppliers' antibacterial test reports, confirming compliance with new standards to avoid delisting or recall risks.